July 1, 2021
2 mins read

7 EU nations clear Covishield amid travel pass row

Austria, Germany, Slovenia, Greece, Iceland, Ireland and Spain — and Switzerland have cleared the Serum Institute of India’s Covishield, reports Asian Lite News

Seven European Union countries – Austria, Germany, Slovenia, Greece, Iceland, Ireland and Spain – and Switzerland have cleared the Serum Institute of India’s Covishield amid travel pass row, sources have said.

The European Medicines Agency (EMA), the EU’s top medical body, has approved only four vaccines so far – Pfizer-BioNTech’s Comirnaty, US pharma giant Moderna’s Covid vaccine, AstraZeneca shot manufactured and sold in Europe as Vaxzervria, and Johnson & Johnson’s Janssen. Only those who’ve been given these shots are granted vaccination passports, and allowed to travel hassle-free amid the pandemic.

Covishield, manufactured in India by the world’s largest manufacture Serum Institute of India – in partnership with the Oxford University and AstraZeneca – is not on the list. Bharat Biotech’s Covaxin is also not on the EMA list.

The EU does, however, also say “member states may decide to extend this (the certificate) also to EU travellers that received another vaccine”.

Under these rules, Indians – vaccinated with Covishield or Covaxin – may be subject to quarantine if they travel to the EU nations, unless these vaccines are cleared by the respective countries.

On Wednesday, sources in the foreign ministry said India will begin a reciprocal policy when it comes to exemption from quarantine. This would mean that unless the European Union accepts Covishield and Covaxin certificates, their certificates will not be accepted in the country and people from EU will face mandatory quarantine upon arrival in India.

Adar Poonawalla on Wednesday said the Serum Institute is hoping the European drug regulators will approve Covishield in a few weeks.

The Serum Institute has applied through AstraZeneca, Mr Poonawalla said at at the India Global Forum, according to reports; and it was “just a matter of time” since the vaccine was approved by the World Health Organization and the UK’s health care regulator.

Earlier on Monday, he had tweeted: “I realise that a lot of Indians who have taken Covishield are facing issues with travel to the E.U., I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries. (sic)”

Last month, the Indian government had opposed to the idea of a “vaccine passports” at a meeting of health ministers from G7 countries.

“Expressed India’s concern and strong opposition to “vaccine passport” at this juncture of the pandemic. With vaccine coverage as a percentage of population in developing countries still low compared to developed countries, such an initiative could prove to be highly discriminatory. (sic)” Health Minister Dr Harsh Vardhan had tweeted after the meeting.

ALSO READ-Accept Indian vaccines or face mandatory quarantine, India tells EU

READ MORE-Limited vax supply key issue for many EU nations

Previous Story

Covid-19 will change the world’s geography

Next Story

Jordan king holds talks with Abbas ahead of Biden summit

Latest from -Top News

ED Action Sparks Congress Uprising

Demonstrations held across all state capitals and district headquarters, marking a coordinated pushback against recent legal moves, including a chargesheet in the National Herald case and the continued questioning of businessman Robert

India-Russia Tourism Hits Fast Track

Indian tourists to Russia doubled in 2024 to over 120,000, while Russian visits to India reached 160,000—surpassing 2021-22 combined. The Indian Embassy estimates mutual tourist numbers could exceed 450,000 by 2025. India

Vance to visit India next week

Vice President JD Vance and the Second Family will travel to Italy and India from April 18 to April 24 US Vice President JD Vance is scheduled to visit India next week.
Go toTop

Don't Miss

Serum Institute says Covishield is most affordable jab

SII, which manufactures the AstraZeneca vaccine Covishield at its Pune

Serum Institute to start vaccine production in London

In an interview with The Times, CEO of Serum Institute